The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Metformin reduces systemic methylglyoxal levels in type 2 diabetes.
Abstract
Methylglyoxal (MG) is a reactive alpha-dicarbonyl that is thought to contribute to diabetic complications either as a direct toxin or as a precursor for advanced glycation end products. It is produced primarily from triose phosphates and is detoxified to D-lactate (DL) by the glyoxalase pathway. Because guanidino compounds can block dicarbonyl groups, we have investigated the effects of the diamino biguanide compound metformin and of hyperglycemia on MG and its detoxification products in type 2 diabetes. MG and DL were measured by high-performance liquid chromatography in plasma from 57 subjects with type 2 diabetes. Of these subjects, 27 were treated with diet, sulfonylureas, or insulin (nonmetformin), and 30 were treated with metformin; 28 normal control subjects were also studied. Glycemic control was determined by HbA1c. MG was significantly elevated in diabetic subjects versus the normal control subjects (189.3 +/- 38.7 vs. 123.0 +/- 37 nmol/l, P = 0.0001). MG levels were significantly reduced by high-dosage (1,500-2,500 mg/day) metformin (158.4 +/- 44.2 nmol/l) compared with nonmetformin (189.3 +/- 38.7 nmol/l, P = 0.03) or low-dosage (< or = 1,000 mg/day) metformin (210.98 +/- 51.0 nmol/l, P = 0.001), even though the groups had similar glycemic control. Conversely, DL levels were significantly elevated in both the low- and high-dosage metformin groups relative to the nonmetformin group (13.8 +/- 7.7 and 13.4 +/- 4.6 vs. 10.4 +/- 3.9 micromol/l, P = 0.03 and 0.06, respectively). MG correlated with rising HbA1c levels (R = 0.4, P = 0.03, slope = 13.2) in the nonmetformin subjects but showed no increase with worsening glycemic control in the high-dosage metformin group (R = 0.0004, P = 0.99, slope = 0.02). In conclusion, MG is elevated in diabetes and relates to glycemic control. Metformin reduces MG in a dose-dependent fashion and minimizes the effect of worsening glycemic control on MG levels. To the extent that elevated MG levels lead to their development, metformin treatment may protect against diabetic complications by mechanisms independent of its antihyperglycemic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glycation and Diabetic Complications
Brownlee, M. (1994) · Diabetes · doi:10.2337/diab.43.6.836 · Cited by 632
Relation between Complications of Type I Diabetes Mellitus and Collagen-Linked Fluorescence
Monnier, V. M., Vishwanath, V., Frank, K. E., Elmets, C. A., Dauchot, P., & Kohn, R. R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602133140702 · Cited by 585
Glycation Products and the Pathogenesis of Diabetic Complications
Brownlee, M. (1992) · Diabetes Care · doi:10.2337/diacare.15.12.1835 · Cited by 495
Vander Jagt, D. L., Robinson, B., Taylor, K. K., & Hunsaker, L. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42844-x · Cited by 280
Identification of Fructose 3-Phosphate in the Lens of Diabetic Rats
Szwergold, B. S., Kappler, F., & Brown, T. R. (1990) · Science · doi:10.1126/science.2300805 · Cited by 213
Self-citationWells‐Knecht, K. J., Feather, M. S., & Baynes, J. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90146-n · Cited by 118
Metabolism of Fructose-3-phosphate in the Diabetic Rat Lens
Lal, S., Szwergold, B. S., Taylor, A. H., Randall, W. C., Kappler, F. E., Wells‐Knecht, K. J., Baynes, J., & Brown, T. R. (1995) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1995.1220 · Cited by 102
Self-citationHammes, H. P., Martin, S., Federlin, K., Geisen, K., & Brownlee, M. (1992) · Proceedings of the National Academy of Sciences · Cited by 82
3-Deoxyglucosone Crosslinks Proteins under Physiological Conditions
Kato, H., Shin, D. B., & Hayase, F. (1987) · Agricultural and Biological Chemistry · doi:10.1271/bbb1961.51.2009 · Cited by 71
The reaction of some dicarbonyl sugars with aminoguanidine
Hirsch, J., Petráková, E., & Feather, M. S. (1992) · Carbohydrate Research · doi:10.1016/s0008-6215(00)90999-6 · Cited by 64
Cited by
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus
Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01129-9 · Cited by 513
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468
Thornalley (2008) · Drug Metabolism and Drug Interactions · doi:10.1515/dmdi.2008.23.1-2.125 · Cited by 480
Metadata
- Authors
- Beisswenger, P. J., Howell, S. K., Touchette, A. D., Lal, S., & Szwergold, B. S.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1999-01-01
- Volume
- 48
- Issue
- 1
- Pages
- 198-202
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2113746520
- Cited by
- 446
- References
- 14
- FWCI
- 6.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin reduces systemic methylglyoxal levels in type 2 diabetes. https://app.cochat.ai/papers/10.2337/diabetes.48.1.198
- The paper
- Beisswenger, P. J., Howell, S. K., Touchette, A. D., Lal, S., & Szwergold, B. S. (1999). Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. https://doi.org/10.2337/diabetes.48.1.198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.